FerGene
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
245 Main St, Cambridge, Massachusetts, 0...Phone Number
(617) 865-5780Website
www.fergene.comRevenue
<$5 MillionIndustry
About FerGene
FerGene Org Chart
Is FerGene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if FerGene has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at FerGene
Click to see if FerGene had a recent Job posting/layoffs
Funding: Get notified immidiatlly once FerGene has new funding data
Check out if FerGene is spiking on competitors!
FerGene, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on FerGene recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when FerGene launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
FerGene is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
FerGene is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about FerGene.
FerGene Tech Stack
A closer look at the technologies used by FerGene
Most Recent Scoops
FerGene News & Media
Landmark Study in Non-Muscle Invasive Bladder Cancer Evaluating Breakthrough Investigational Gene Therapy Nadofaragene Firadenovec Published in The Lancet Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FerGene Inc., today announced that The Lancet Oncology published the Phase 3 data from the landmark U.S. clinical trial evaluating an investigational gene therapy, nadofaragene firadenovec (rAd-IFN/Syn3), for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). In the study, patients received nadofaragene firadenovec, an intravesical therapy given once every three months that is beliFerGene Appoints Top Biotech Leaders to Executive Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FerGene, Inc., a privately held gene therapy company dedicated to revolutionizing the treatment of bladder cancer, today announced the appointment of top biotech leaders to its executive team. The newly appointed leaders bring a wealth of experience and proven track records of success in oncology and urology to the company, as FerGene prepares to potentially commercialize the first gene therapy for patients living with non-muscle invasive bladder cancer (NMIBC
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding FerGene
FerGene Inc. is a gene therapy company committed to revolutionizing the treatment of bladder cancer through its innovative science and unparalleled commitment to patient care. Founded in 2019, through a collaboration between Blackstone Life Sciences and Ferring Pharmaceuticals, FerGene Inc. is singularly focused on evolving the bladder cancer treat... Read More